Treats predominantly classic subfoveal choroidal neovascularization (CNV) due to…. Sold as Visudyne. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 1 application for Verteporfin (sold as Visudyne), first approved Apr 12, 2000, with 2 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Visudyne | Part B | $1.5M | -6% | 806 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Apr 12, 2000 | VisudyneNDA 21119 · New molecular entity | Bausch Lomb Ireland | 16 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
